Track topics on Twitter Track topics that are important to you
Flex Pharma, a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced that the Board of Directors has appointed William McVicar, Ph.D., as President and Chief Executive Officer […]
The post Flex Pharma names William McVicar President and CEO appeared first on CenterWatch News Online.
Original Article: Flex Pharma names William McVicar President and CEONEXT ARTICLE
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...